Athenex, Inc. Loss Submission Form

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Athenex, Inc. (NASDAQ: ATNX) who purchased shares between August 7, 2019 and February 26, 2021. The action, which was filed in the United States District Court for the Western District of New York, alleges that the Company violated federal securities laws.

(i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) the Company’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Shareholders have until May 3, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

To learn more and keep informed, complete this form >